Advancements in heparosan production through metabolic engineering and improved fermentation.
Carbohydr Polym
; 331: 121881, 2024 May 01.
Article
in En
| MEDLINE
| ID: mdl-38388039
ABSTRACT
Heparin is one of the most widely used natural drugs, and has been the preferred anticoagulant and antithrombotic agent in the clinical setting for nearly a century. Heparin also shows increasing therapeutic potential for treating inflammation, cancer, and microbial and viral diseases, including COVID-19. With advancements in synthetic biology, heparin production through microbial engineering of heparosan offers a cost-effective and scalable alternative to traditional extraction from animal tissues. Heparosan serves as the starting carbon backbone for the chemoenzymatic synthesis of bioengineered heparin, possessing a chain length that is critically important for the production of heparin-based therapeutics with specific molecular weight (MW) distributions. Recent advancements in metabolic engineering of microbial cell factories have resulted in high-yield heparosan production. This review systematically analyzes the key modules involved in microbial heparosan biosynthesis and the latest metabolic engineering strategies for enhancing production, regulating MW, and optimizing the fermentation scale-up of heparosan. It also discusses future studies, remaining challenges, and prospects in the field.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Disaccharides
/
Metabolic Engineering
Language:
En
Journal:
Carbohydr Polym
/
Carbohydrate polymers
Year:
2024
Document type:
Article